UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

Therapeutic Advances in Neurological Disorders, 2015-01, Vol.8 (1), p.31-45

2015

Link zum Volltext

Verfügbarkeit prüfen

Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis

Multiple sclerosis, 2021-02, Vol.27 (2), p.220-231

2021

Link zum Volltext

Verfügbarkeit prüfen

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

PloS one, 2012-11, Vol.7 (11), p.e50101-e50101

2012

Link zum Volltext

Verfügbarkeit prüfen

Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis

Multiple sclerosis, 2021-01, Vol.27 (1), p.52-60

2021

Link zum Volltext

Verfügbarkeit prüfen

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients

Journal of lipid research, 2017-02, Vol.58 (2), p.403-411

2017

Link zum Volltext

Verfügbarkeit prüfen

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Brain (London, England : 1878), 2017-09, Vol.140 (9), p.2426-2443

2017

Link zum Volltext

Verfügbarkeit prüfen

Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

Multiple sclerosis, 2021-11, Vol.27 (13), p.2001-2013

2021

Link zum Volltext

Verfügbarkeit prüfen

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis

Multiple sclerosis, 2019-04, Vol.25 (4), p.541-553

2019

Link zum Volltext

Verfügbarkeit prüfen

CSF Markers of Oxidative Stress Are Associated with Brain Atrophy and Iron Accumulation in a 2-Year Longitudinal Cohort of Early MS

International journal of molecular sciences, 2023-06, Vol.24 (12), p.10048

2023

Link zum Volltext

Verfügbarkeit prüfen

The clinical and paraclinical correlates of employment status in multiple sclerosis

Neurological sciences, 2022-03, Vol.43 (3), p.1911-1920

2022

Link zum Volltext

Verfügbarkeit prüfen

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients

Journal of lipid research, 2015-10, Vol.56 (10), p.2010-2018

2015

Link zum Volltext

Verfügbarkeit prüfen

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab

Frontiers in immunology, 2023-06, Vol.14, p.1149629-1149629

2023

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences

Multiple sclerosis, 2023-10, Vol.29 (11-12), p.1437-1451

2023

Link zum Volltext

Verfügbarkeit prüfen

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study

NeuroImage clinical, 2018-01, Vol.17, p.444-451

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up

Frontiers in immunology, 2022-02, Vol.13, p.818325-818325

2022

Link zum Volltext

Verfügbarkeit prüfen

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis

NeuroImage clinical, 2017-01, Vol.15, p.769-779

2017

Link zum Volltext

Verfügbarkeit prüfen

Periventricular gradient of T1 tissue alterations in multiple sclerosis

NeuroImage clinical, 2022-01, Vol.34, p.103009-103009, Article 103009

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Therapeutic advances in neurological disorders, 2024-01, Vol.17, p.17562864231221331-17562864231221331

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(169)

Publikationsform

Artikel
(187)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(162)
Life Sciences & Biomedicine
(158)
Multiple Sclerosis
(133)
Neurosciences & Neurology
(128)
Clinical Neurology
(111)
Humans
(108)
Neurosciences
(74)
Female
(71)
Adult
(67)
Male
(64)
Magnetic Resonance Imaging
(47)
Disease Progression
(39)
Middle Aged
(39)
Neurology
(32)
Multiple Sclerosis - Drug Therapy
(31)
Atrophy
(28)
Mri
(27)
Recurrence
(27)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(26)
Patients
(26)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis

CSF Markers of Oxidative Stress Are Associated with Brain Atrophy and Iron Accumulation in a 2-Year Longitudinal Cohort of Early MS

The clinical and paraclinical correlates of employment status in multiple sclerosis

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis

Periventricular gradient of T1 tissue alterations in multiple sclerosis

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Suchergebnisse filtern